瑞舒伐他汀对自发性高血压大鼠血压、肠系膜动脉血管结构和舒张功能的影响

发布时间：2018-02-21 23:32

本文关键词： 高血压瑞舒伐他汀肠系膜动脉血管结构舒张功能　出处：《中华高血压杂志》2015年05期 　论文类型：期刊论文

【摘要】：目的观察瑞舒伐他汀对自发性高血压大鼠(SHR)血压、肠系膜三级动脉血管结构和舒张功能的影响。方法 12周龄雄性SHR 32只,随机分为瑞舒伐他汀治疗组[SHR-R,10mg/(kg·d),n=16]和SHR组(SHR,n=16),对应周龄雄性Wistar Kyoto大鼠作为正常血压组(WKY,n=16)。采用无创尾袖法测量大鼠尾动脉血压;应用计算机图像分析计算血管管壁面积/管腔面积(W/L)、管壁厚度/管腔半径(WT/LR)。采用PowerLab生物信息采集系统分别检测离体肠系膜三级动脉对不同浓度血管活性物质的舒张反应。结果 SHR的收缩压明显高于同龄WKY大鼠(P0.01)。瑞舒伐他汀治疗4、8周末,SHR-R的收缩压明显低于未治疗的SHR[治疗4周收缩压:SHR-R(180.0±14.6)比SHR(200.3±13.9)mm Hg;8周:SHR-R(180.1±13.5)比SHR(189.9±10.1)mm Hg,均P0.01]。治疗4周,肠系膜三级动脉W/L和WT/LR组间差异无统计学意义(P0.05)。治疗8周,SHR-R肠系膜三级动脉W/L及WT/LR明显降低[W/L:SHR-R 0.51±0.21比SHR 1.82±0.96;WT/LR:SHR-R 0.23±0.04比SHR 0.53±0.29,均P0.01],且SHR-R与WKY大鼠的WT/LR相比,差异无统计学意义(P0.05)。治疗4周,SHR-R的肠系膜三级动脉血管内皮依赖性舒张功能明显增强[最大舒张百分比(Emax):SHR-R(47.41±10.74)%比SHR(29.10±7.35)%,WKY(83.85±5.17)%;舒张反应敏感性(pD2):SHR-R 6.39±0.90比SHR5.96±0.58,WKY 8.34±0.21,均P0.01],非内皮依赖性舒张功能也明显增强[Emax:SHR-R(75.23±20.10)%比SHR(46.13±11.45)%,WKY(96.28±2.68)%;pD2值:SHR-R 6.72±0.44比SHR 5.56±0.23,WKY 7.84±0.13,均P0.01]。治疗8周与治疗4周比较,差异无统计学意义(P0.05)。结论瑞舒伐他汀治疗可轻度降低SHR的血压,治疗4周即可改善血管舒张功能,治疗8周可抑制肠系膜三级动脉血管肥厚,并且舒张功能的改善先于血管结构的变化。
[Abstract]:Objective to observe the effects of rosuvastatin on blood pressure, mesenteric tertiary artery structure and diastolic function in spontaneously hypertensive rats. The rats were randomly divided into two groups: the control group [SHR-Rn 10 mg / kg 路danzhi16] and the SHR group respectively. The male Wistar Kyoto rats were used as the normal blood pressure group. The caudal artery blood pressure was measured by non-invasive caudal cuff method. The wall area / lumen area of blood vessel were calculated by computer image analysis, and the thickness of vessel wall / radius of vessel cavity were calculated by WTP / LRX. The PowerLab bioinformatics system was used to detect the relaxation of isolated mesenteric tertiary artery to different concentrations of vasoactive substances. Results the systolic blood pressure of SHR was significantly higher than that of WKY rats of the same age (P 0.01). The systolic blood pressure of SHR-R was significantly lower than that of untreated SHR at the end of 4 weeks. The systolic blood pressure of SHR-R was significantly lower than that of SHR(200.3 卤13.9mm Hg180.1 卤13.5mHg180.1 卤13.5mHg. the systolic blood pressure of SHR-R was significantly lower than that of untreated SHR at the end of 4 weeks (P0.01), and the systolic blood pressure of SHR-R was significantly lower than that of SHR(200.3 卤13.9mm Hg180.1 卤13.5mm. the systolic blood pressure of SHR-R was significantly lower than that of untreated SHR (P 0.01). There was no significant difference between the three mesenteric artery W / L and WT/LR group (P 0.05). After 8 weeks of treatment, the WR and WT/LR of the third mesenteric artery of SHR-R significantly decreased [W / L: SHR-R 0.51 卤0.21 vs SHR 1.82 卤0.96 WTLRVSHR-R 0.23 卤0.04 vs SHR 0.53 卤0.29, all P 0.01], and SHR-R compared with WT/LR of WKY rats. The endothelium-dependent diastolic function of the mesenteric third grade artery was significantly enhanced after 4 weeks of treatment with SHR-R. [the maximal diastolic percentage was 47.41 卤10.74% vs SHR(29.10 卤7.35% vs SHR(29.10 卤7.35%, the sensitivity of dilatation was pD2W SHR-R 6.39 卤0.90 vs SHR5.96 卤0.58WKY 8.34 卤0.21, all P0.01]. The function was also significantly enhanced [Emax:SHR-R(75.23 卤20.10% vs SHR(46.13 卤11.45% vs SHR(46.13 卤11.45%] [SHR(46.13 卤11.45% vs 96.28 卤2.68%] pD2: SHR-R 6.72 卤0.44 vs SHR 5.56 卤0.23 WKY 7.84 卤0.13, respectively (P0.01). Conclusion Risuvastatin can slightly reduce the blood pressure of SHR, improve the vasodilation function at 4 weeks and inhibit the hypertrophy of mesenteric third order artery after 8 weeks. The improvement of diastolic function preceded the change of vascular structure.
【作者单位】：福建医科大学附属第一医院福建省高血压研究所;
【分类号】：R965

【参考文献】